Download Sample
Add to CartGlobal Atrial Fibrillation Drugs Market Growth, Share, Size, Trends and Forecast (2024 - 2030)
By Product;
Antiarrhythmic Drugs and Anticoagulant Drugs.By Atrial Fibrillation Type;
Paroxysmal, Persistent and Permanent.By Application;
Heart Rhythm Control and Heart Rate Control.By Administration Route;
Oral and Injectable.By End-Use;
Hospitals, Cardiac Centers, Ambulatory Surgical Centers and Others.By Geography;
North America, Europe, Asia Pacific, Middle East and Africa and Latin America - Report Timeline (2020 - 2030).Introduction
Global Atrial Fibrillation Drugs Market (USD Million), 2020 - 2030
In the year 2023, the Global Atrial Fibrillation Drugs Market was valued at USD 13,308.30 million. The size of this market is expected to increase to USD 17,046.72 million by the year 2030, while growing at a Compounded Annual Growth Rate (CAGR) of 3.6%.
The global atrial fibrillation drugs market is a dynamic sector within the broader pharmaceutical landscape, characterized by a myriad of factors including technological advancements, evolving treatment paradigms, and the increasing prevalence of atrial fibrillation (AF) worldwide. Atrial fibrillation, a common cardiac arrhythmia marked by irregular and often rapid heart rate, presents significant challenges to healthcare systems globally due to its association with increased risk of stroke, heart failure, and mortality.
One of the primary drivers propelling the growth of the atrial fibrillation drugs market is the escalating prevalence of this condition, particularly among the aging population. With the aging demographic in many parts of the world, the incidence of atrial fibrillation is expected to rise, necessitating the development of more effective pharmacotherapies to manage the condition and its associated complications.
The growing awareness among both healthcare professionals and patients regarding the importance of early diagnosis and appropriate management of atrial fibrillation is fostering the demand for novel therapeutic interventions. This increased awareness, coupled with advancements in diagnostic technologies, is anticipated to drive the expansion of the atrial fibrillation drugs market in the coming years.
Demographic trends and heightened awareness, the market is also influenced by a continuous stream of research and development activities aimed at discovering innovative treatment modalities. Pharmaceutical companies are actively engaged in the development of novel drugs targeting specific pathways and mechanisms implicated in the pathogenesis of atrial fibrillation, thereby expanding the treatment options available to patients and clinicians.
The market landscape is shaped by regulatory dynamics and healthcare policies that govern the approval, reimbursement, and accessibility of atrial fibrillation drugs. Changes in regulatory frameworks, such as expedited approval pathways for breakthrough therapies and initiatives to promote affordable access to essential medications, can significantly impact the market dynamics and competitive landscape.
Overall, the global atrial fibrillation drugs market presents a dynamic and evolving landscape characterized by innovation, demographic shifts, regulatory developments, and increasing disease burden. As stakeholders across the healthcare continuum strive to address the unmet needs of patients with atrial fibrillation, the market is poised for continued growth and transformation in the years to come.
Global Atrial Fibrillation Drugs Market Report Snapshot
| Parameters | Description |
|---|---|
| Market | Global Atrial Fibrillation Drugs Market |
| Study Period | 2020 - 2030 |
| Base Year (for Atrial Fibrillation Drugs Market Size Estimates) | 2023 |
| Drivers |
|
| Restraints |
|
| Opportunities |
|
Segment Analysis
The global atrial fibrillation drugs market has been witnessing significant growth, primarily driven by the rising prevalence of atrial fibrillation worldwide. Atrial fibrillation, characterized by irregular heartbeats, is a common cardiac arrhythmia affecting millions of individuals globally. As a result, the demand for effective drugs to manage atrial fibrillation has surged, propelling the growth of the market.
In terms of segmentation, the atrial fibrillation drugs market can be classified based on drug class, distribution channel, and geography. Among the drug classes, anti-arrhythmic drugs, anticoagulant drugs, and non-steroidal anti-inflammatory drugs (NSAIDs) are the key segments contributing to market revenue. Anti-arrhythmic drugs such as amiodarone, flecainide, and propafenone are commonly prescribed to restore normal heart rhythm and prevent recurrences of atrial fibrillation episodes. Anticoagulant drugs such as warfarin, dabigatran, rivaroxaban, and apixaban are vital for reducing the risk of stroke and systemic embolism in patients with atrial fibrillation.
The distribution channel segment encompasses hospital pharmacies, retail pharmacies, and online pharmacies. Hospital pharmacies represent a significant revenue contributor owing to the high volume of atrial fibrillation patients receiving treatment in hospital settings. However, with the increasing trend of online purchasing and the convenience it offers, the online pharmacies segment is expected to witness substantial growth during the forecast period.
Geographically, the atrial fibrillation drugs market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America dominates the market share owing to the high prevalence of atrial fibrillation, well-established healthcare infrastructure, and increasing adoption of novel therapeutics. Europe follows suit, with countries like Germany, the UK, and France contributing significantly to market revenue. Meanwhile, the Asia Pacific region is anticipated to witness rapid growth due to the burgeoning geriatric population, changing lifestyle patterns, and improving access to healthcare facilities.
In conclusion, the global atrial fibrillation drugs market is poised for significant expansion fueled by the increasing incidence of atrial fibrillation and the growing demand for effective treatment options. With advancements in drug development, expanding distribution channels, and increasing healthcare awareness, the market is likely to witness sustained growth in the coming years.
Global Atrial Fibrillation Drugs Segment Analysis
In this report, the Global Atrial Fibrillation Drugs Market has been segmented by Product, Atrial Fibrillation Type, Application, Administration Route, End-Use and Geography.
Global Atrial Fibrillation Drugs Market, Segmentation by Product
The Global Atrial Fibrillation Drugs Market has been segmented by Product into Antiarrhythmic Drugs and Anticoagulant Drugs.
Antiarrhythmic drugs form a significant portion of the market, aimed at regulating the heart's rhythm and controlling the episodes of AF. These drugs work by stabilizing the heart's electrical activity, thereby reducing the frequency and severity of atrial fibrillation episodes. They are often prescribed to patients experiencing persistent or recurrent AF to manage symptoms and improve quality of life.
On the other hand, anticoagulant drugs are essential in the management of AF due to the increased risk of stroke associated with the condition. AF can lead to the formation of blood clots in the atria, which can travel to the brain and cause a stroke. Anticoagulants help prevent clot formation by inhibiting the clotting factors in the blood, thus reducing the risk of stroke and other thromboembolic complications in AF patients.
The market for atrial fibrillation drugs is characterized by intense competition among pharmaceutical companies striving to develop more effective and safer treatment options. Additionally, factors such as an aging population, lifestyle changes leading to an increased prevalence of risk factors like obesity and hypertension, and advancements in medical technology contribute to the growth of this market.
Moreover, with ongoing research and development efforts focused on novel therapeutic approaches, such as targeted therapies and non-pharmacological interventions like catheter ablation, the landscape of atrial fibrillation treatment is continuously evolving. This evolution is expected to further drive market growth and improve patient outcomes in the years to come.
Global Atrial Fibrillation Drugs Market, Segmentation by Atrial Fibrillation Type
The Global Atrial Fibrillation Drugs Market has been segmented by Atrial Fibrillation Type into Paroxysmal, Persistent and Permanent.
Paroxysmal atrial fibrillation refers to episodes that come and go, often lasting for a few seconds to hours before spontaneously converting to normal sinus rhythm. This type poses challenges in terms of predicting and managing episodes, necessitating medications that can help in controlling heart rhythm and reducing the frequency and severity of episodes. The market for drugs targeting paroxysmal AF is thus focused on antiarrhythmic agents and rate control medications that can effectively manage these intermittent episodes.
Persistent atrial fibrillation is characterized by episodes that last longer than seven days, requiring medical intervention to restore normal heart rhythm. The drugs targeting persistent AF aim to not only restore sinus rhythm but also maintain it over the long term. Antiarrhythmic medications play a crucial role in this regard, along with other adjunctive therapies such as electrical cardioversion and catheter ablation. The market for drugs addressing persistent AF is driven by the need for effective maintenance of sinus rhythm while minimizing adverse effects and risks associated with long-term therapy.
Permanent atrial fibrillation represents a more advanced stage of the condition where attempts to restore sinus rhythm have been unsuccessful or are not considered feasible. Management in permanent AF focuses on controlling heart rate and preventing complications such as stroke and heart failure. The market for drugs targeting permanent AF primarily revolves around rate control medications, anticoagulants to reduce the risk of thromboembolic events, and drugs targeting comorbidities such as hypertension and heart failure.
Overall, the market for atrial fibrillation drugs is witnessing robust growth fueled by advancements in pharmacotherapy, increasing awareness about the condition, and the growing burden of atrial fibrillation globally. However, challenges remain in terms of balancing efficacy with safety, particularly in the context of managing different types of AF and addressing the varied needs of patients. Ongoing research and development efforts are thus focused on identifying novel therapeutic targets, optimizing existing treatment modalities, and personalizing therapies to improve outcomes for patients with atrial fibrillation.
Global Atrial Fibrillation Drugs Market, Segmentation by Application
The Global Atrial Fibrillation Drugs Market has been segmented by Application into Heart Rhythm Control and Heart Rate Control.
One of the key categorizations within the market is based on application, with drugs primarily aimed at either heart rhythm control or heart rate control. Heart rhythm control medications are designed to restore and maintain normal heart rhythm, thereby reducing the frequency and severity of AF episodes. These drugs work by regulating the electrical impulses that coordinate heartbeats, often through the use of antiarrhythmic agents. They are particularly beneficial for patients with persistent or recurrent AF seeking to achieve sinus rhythm.
On the other hand, heart rate control drugs focus on managing the rapid and irregular heart rate associated with AF. By slowing down the heart rate, these medications help alleviate symptoms such as palpitations, shortness of breath, and fatigue, improving patients' quality of life. Beta-blockers, calcium channel blockers, and digoxin are commonly prescribed for heart rate control in AF patients.
The choice between heart rhythm control and heart rate control strategies depends on various factors, including the severity of symptoms, patient preferences, comorbidities, and overall health status. In some cases, a combination of both approaches may be recommended to achieve optimal outcomes. As healthcare providers strive to personalize treatment plans for AF patients, the market for atrial fibrillation drugs continues to evolve, with ongoing research and development efforts aimed at enhancing efficacy, safety, and patient adherence.
Advancements in technology and the emergence of novel therapeutic modalities such as catheter ablation and left atrial appendage closure, the landscape of AF management is undergoing significant transformation. These interventions complement pharmacological therapies, offering additional options for patients who are refractory to drug treatment or require more definitive solutions. Overall, the global atrial fibrillation drugs market is poised for further expansion, driven by the growing burden of AF and the quest for innovative solutions to address the unmet needs of patients with this cardiovascular condition.
Global Atrial Fibrillation Drugs Market, Segmentation by Administration Route
The Global Atrial Fibrillation Drugs Market has been segmented by Administration Route into Oral and Injectable.
Oral medications form a cornerstone of atrial fibrillation management, offering convenience and ease of administration for patients. These drugs often include anticoagulants such as warfarin, dabigatran, rivaroxaban, and apixaban, which help prevent blood clots and reduce the risk of stroke. Additionally, antiarrhythmic drugs like flecainide, propafenone, and amiodarone may be prescribed to control heart rhythm and prevent episodes of atrial fibrillation.
Injectable medications are also crucial in the treatment of atrial fibrillation, particularly in acute settings or when oral administration is not feasible. Injectable anticoagulants such as heparin and its derivatives are commonly used for rapid anticoagulation in emergency situations or during surgical procedures. Additionally, intravenous antiarrhythmic agents like ibutilide and dofetilide may be administered in hospital settings to restore normal heart rhythm.
Both oral and injectable medications play vital roles in the comprehensive management of atrial fibrillation, addressing different aspects of the condition and catering to individual patient needs. The market for these drugs continues to evolve with advancements in pharmacotherapy and the development of novel treatment approaches aimed at improving outcomes and quality of life for patients with atrial fibrillation.
Global Atrial Fibrillation Drugs Market, Segmentation by End-Use
The Global Atrial Fibrillation Drugs Market has been segmented by End-Use into Hospitals, Cardiac Centers, Ambulatory Surgical Centers and Others.
The global atrial fibrillation drugs market is witnessing significant growth, driven by increasing prevalence of atrial fibrillation and advancements in treatment options. The market is segmented by end-use into hospitals, cardiac centers, ambulatory surgical centers, and others. Hospitals represent a substantial portion of the market due to their role as primary treatment centers for cardiovascular conditions.
The rising burden of atrial fibrillation cases worldwide, hospitals are equipped with the necessary infrastructure and expertise to diagnose and treat the condition effectively. Cardiac centers also play a crucial role in the market, offering specialized care and advanced treatment options for atrial fibrillation patients. Ambulatory surgical centers are emerging as key contributors to the market, providing outpatient procedures and treatments for atrial fibrillation.
Healthcare facilities such as specialty clinics and diagnostic centers are also contributing to the market growth by providing comprehensive care and diagnostic services for atrial fibrillation patients. Overall, the increasing demand for effective atrial fibrillation drugs across various healthcare settings is expected to drive the growth of the global market in the coming years.
Global Atrial Fibrillation Drugs Market, Segmentation by Geography
In this report, the Global Atrial Fibrillation Drugs Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.
Global Atrial Fibrillation Drugs Market Share (%), by Geographical Region, 2023
The global atrial fibrillation drugs market is segmented by geography, reflecting the diverse regional dynamics shaping the demand for treatments targeting this cardiac condition. North America stands out as a key market due to its advanced healthcare infrastructure, high prevalence of atrial fibrillation, and significant investments in research and development. The region is characterized by a strong presence of pharmaceutical companies focusing on cardiovascular therapies, driving innovation and adoption of novel treatment approaches. Additionally, favorable reimbursement policies and increasing awareness among patients contribute to the growth of the atrial fibrillation drugs market in North America.
Europe represents another prominent market for atrial fibrillation drugs, fueled by a growing geriatric population and rising incidences of lifestyle-related risk factors such as obesity and hypertension. Countries like Germany, France, and the United Kingdom are at the forefront of adopting advanced treatment modalities, driving market expansion. Moreover, initiatives promoting early diagnosis and management of atrial fibrillation contribute to the market growth in Europe.
The Asia-Pacific region exhibits immense growth potential in the atrial fibrillation drugs market, propelled by rapid urbanization, changing dietary habits, and the increasing prevalence of atrial fibrillation due to a growing aging population. Emerging economies like China and India are witnessing a surge in healthcare expenditure, coupled with a rising focus on improving access to quality healthcare services, which augurs well for market development. Moreover, strategic collaborations between global pharmaceutical companies and local players facilitate market penetration and product availability across diverse geographies within the Asia-Pacific region.
Latin America and the Middle East & Africa regions are also expected to contribute to the growth of the atrial fibrillation drugs market, albeit at a comparatively slower pace. Factors such as improving healthcare infrastructure, rising disposable income, and increasing awareness about atrial fibrillation and its management drive market expansion in these regions. However, challenges related to regulatory frameworks, healthcare access, and affordability remain significant barriers to market growth in certain countries within these regions.
In conclusion, the global atrial fibrillation drugs market exhibits a complex landscape shaped by regional variations in healthcare infrastructure, demographics, and regulatory environments. Understanding and addressing these diverse factors are crucial for pharmaceutical companies to capitalize on emerging opportunities and effectively navigate challenges in different geographical markets.
Market Trends
This report provides an in depth analysis of various factors that impact the dynamics of Global Atrial Fibrillation Drugs Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.
Drivers, Restraints and Opportunity Analysis
Drivers:
- Aging population
- Prevalence of atrial fibrillation
- Awareness and diagnosis
-
Research and development -Research and development (R&D) in the global atrial fibrillation drugs market play a pivotal role in shaping the landscape of treatment options available to patients. Pharmaceutical companies, academic institutions, and research organizations are actively engaged in developing innovative therapies to address the unmet medical needs of individuals suffering from atrial fibrillation.
One significant area of R&D focuses on the discovery and development of novel drug candidates targeting specific molecular pathways involved in the pathogenesis of atrial fibrillation. These efforts aim to identify compounds with improved efficacy and safety profiles compared to existing treatments, thereby offering patients better therapeutic options. Advancements in pharmacogenomics and personalized medicine also contribute to the development of tailored therapies that can optimize treatment outcomes based on individual patient characteristics.
Research efforts are directed towards enhancing the understanding of atrial fibrillation's underlying mechanisms and risk factors, which can inform the development of targeted therapies. This includes investigating genetic predispositions, structural heart abnormalities, electrophysiological changes, and comorbidities associated with atrial fibrillation. By elucidating these aspects, researchers can identify new druggable targets and develop more precise therapeutic interventions.
Drug discovery, R&D activities encompass preclinical and clinical studies aimed at evaluating the safety, efficacy, and pharmacokinetics of investigational compounds. These studies involve rigorous testing in laboratory models and human subjects to assess a drug candidate's potential therapeutic benefits and adverse effects. Clinical trials, in particular, play a crucial role in demonstrating the efficacy of novel drugs and obtaining regulatory approval for their commercialization.
Ongoing R&D efforts also focus on improving existing treatment modalities, such as anti-arrhythmic drugs and anticoagulants, by refining their formulations, enhancing their delivery systems, and exploring combination therapies. This includes the development of sustained-release formulations, novel drug delivery devices, and combination regimens that target multiple facets of atrial fibrillation management simultaneously.
Overall, research and development activities in the global atrial fibrillation drugs market are essential for driving innovation, expanding treatment options, and improving patient outcomes. With continued investment in R&D, coupled with collaborative efforts across academia, industry, and regulatory agencies, there is considerable potential to advance the field of atrial fibrillation therapeutics and address the evolving needs of patients worldwide.
Restraints:
- Access barriers in emerging markets
- Complexity of atrial fibrillation management
- Resistance to pharmacotherapy
-
Lack of reimbursement policies -The global atrial fibrillation drugs market faces challenges related to the lack of reimbursement policies, which can impact both patients and healthcare providers. Reimbursement policies play a crucial role in determining the accessibility and affordability of atrial fibrillation treatments, including antiarrhythmic and anticoagulant drugs.
In many healthcare systems, the availability of reimbursement for prescription medications is essential for patients to afford necessary treatments. However, reimbursement policies for atrial fibrillation drugs vary widely across different regions and healthcare systems. Some patients may face difficulties in accessing these medications due to limited coverage or high out-of-pocket costs, especially for newer or more expensive therapies.
Healthcare providers also face challenges related to reimbursement policies when prescribing atrial fibrillation drugs. They must navigate complex reimbursement criteria and paperwork, which can be time-consuming and may deter them from prescribing certain medications. Additionally, inadequate reimbursement for atrial fibrillation treatments can strain healthcare budgets and limit resources for patient care and medical innovation.
The lack of reimbursement policies for atrial fibrillation drugs underscores the need for healthcare policymakers and stakeholders to address access barriers and ensure equitable access to effective treatments for patients with this condition. Developing comprehensive reimbursement frameworks that prioritize patient needs, clinical effectiveness, and cost-effectiveness can help improve access to atrial fibrillation drugs and optimize patient outcomes on a global scale. Additionally, efforts to streamline reimbursement processes and enhance communication between healthcare providers, insurers, and patients can facilitate timely access to essential medications and support effective disease management strategies.
Opportunities:
- Awareness campaigns
- Personalized medicine
- Regulatory reforms
-
Collaborations and partnerships -In the global atrial fibrillation (AF) drugs market, collaborations and partnerships play a vital role in driving innovation, expanding market reach, and enhancing the development of novel therapeutic options. Pharmaceutical companies often collaborate with academic institutions, research organizations, and other industry players to leverage complementary expertise, resources, and technologies. These collaborations facilitate the discovery, development, and commercialization of new drugs and treatment modalities for AF.
Partnerships between pharmaceutical companies and medical device manufacturers are also common, particularly in the field of AF treatment. For example, collaborations between drug developers and companies specializing in cardiac rhythm management devices can lead to the integration of pharmaceutical therapies with innovative technologies such as implantable cardioverter-defibrillators (ICDs) and cardiac ablation systems.
Collaborations between pharmaceutical companies and healthcare providers or payers are essential for ensuring access to AF drugs and optimizing patient outcomes. These collaborations often involve real-world evidence generation, health economic assessments, and patient support programs aimed at improving medication adherence and treatment adherence.
Collaborations between pharmaceutical companies and patient advocacy groups are instrumental in raising awareness about AF, addressing unmet patient needs, and advocating for improved access to therapies. These partnerships can also inform drug development efforts by providing insights into patient perspectives, preferences, and priorities.
There has been a notable increase in collaborations between pharmaceutical companies and digital health companies. These collaborations leverage digital technologies such as mobile apps, wearable devices, and remote monitoring solutions to enhance the management of AF through personalized medicine, real-time monitoring of cardiac rhythm, and data-driven insights into treatment effectiveness.
Overall, collaborations and partnerships are integral to advancing innovation, accelerating drug development, and improving patient care in the global atrial fibrillation drugs market. By harnessing the collective expertise and resources of various stakeholders, these collaborations have the potential to address the complex challenges associated with AF and drive positive outcomes for patients worldwide.
Competitive Landscape Analysis
Key players in Global Atrial Fibrillation Drugs Market include.
- AstraZeneca
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Daiichi Sankyo
- GlaxoSmithKline
- Johnson and Johnson (JanssenOrtho)
- Mitsubishi Tanabe Pharma
- Pfizer
- Portola Pharmaceuticals
- Sanofi
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Product
- Market Snapshot, By Atrial Fibrillation Type
- Market Snapshot, By Application
- Market Snapshot, By Administration Route
- Market Snapshot, By End-Use
- Market Snapshot, By Region
- Global Atrial Fibrillation Drugs Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
-
Aging population
-
Prevalence of atrial fibrillation
-
Awareness and diagnosis
-
Research and development
-
- Restraints
-
Access barriers in emerging markets
-
Complexity of atrial fibrillation management
-
Resistance to pharmacotherapy
-
Lack of reimbursement policies
-
- Opportunities
-
Awareness campaigns
-
Personalized medicine
-
Regulatory reforms
-
Collaborations and partnerships
-
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Global Atrial Fibrillation Drugs Market, By Product, 2020 - 2030 (USD Million)
- Antiarrhythmic Drugs
- Anticoagulant Drugs
- Global Atrial Fibrillation Drugs Market, By Atrial Fibrillation Type, 2020 - 2030 (USD Million)
- Paroxysmal
- Persistent
- Permanent
- Global Atrial Fibrillation Drugs Market, By Application, 2020 - 2030 (USD Million)
- Heart Rhythm Control
- Heart Rate Control
- Global Atrial Fibrillation Drugs Market, By Administration Route, 2020 - 2030 (USD Million)
- Oral
- Injectable
- Global Atrial Fibrillation Drugs Market, By End-Use, 2020 - 2030 (USD Million)
- Hospitals
- Cardiac Centers
- Ambulatory Surgical Centers
- Others
- Global Atrial Fibrillation Drugs Market, By Geography, 2020 - 2030 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- South Korea ASEAN (Association of South East Asian Countries)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Global Atrial Fibrillation Drugs Market, By Product, 2020 - 2030 (USD Million)
- Competitive Landscape
- Company Profiles
- AstraZeneca
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Daiichi Sankyo
- GlaxoSmithKline
- Johnson and Johnson (JanssenOrtho)
- Mitsubishi Tanabe Pharma
- Pfizer
- Portola Pharmaceuticals
- Sanofi
- Company Profiles
- Analyst Views
- Future Outlook of the Market